Bio-Techne 2026 10-K/A Amended Annual Report
TECH · CIK 842023 · Form 10-K/A · Fiscal year ended June 30, 2026 · Filed October 28, 2026
3 sections, 172K characters. Original on sec.gov · ·
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K/A
(Amendment No. 1)
| ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the fiscal year ended June 30, 2026, or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the transition period
from to
Commission file number 0-17272
BIO-TECHNE CORPORATION
(Exact name of registrant as specified in its charter)
| Minnesota | 41-1427402 | |
|---|---|---|
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 614 McKinley Place N.E. Minneapolis, MN 55413 | (612) 379-8854 | |
|---|---|---|
| (Address of principal executive offices) (Zip Code) | (Registrant’s telephone number, including area code) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | TECH | The NASDAQ Stock Market LLC |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
|---|---|---|---|
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
As of December 31, 2025, the aggregate market value of the Common Stock held by non-affiliates of the Registrant was $9.1 billion based upon the closing sale price as reported on The Nasdaq Stock Market ($58.81 per share). Shares of Common Stock held by each officer and director and by each person who owns 5% or more of the outstanding Common Stock have been excluded.
As of October 9, 2026, 157,055,564 shares of the Company’s Common Stock ($0.01 par value) were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (the “Form 10-K/A”) to the Annual Report on Form 10-K of Bio-Techne Corporation (the “Company”) for the fiscal year ended June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”) on August 24, 2026 (the “Original Report”), is being filed solely for the purpose of including the information required by Part III of Form 10-K that the Company did not include in the Original Report in reliance on General Instruction G(3) to Form 10-K, which permits this information to be incorporated by reference from a registrant’s definitive proxy statement if the proxy statement is filed within 120 days after fiscal year-end. We are filing this Form 10-K/A to include Part III information in our Form 10-K because we do not intend to file a definitive proxy statement for an annual meeting of shareholders containing such information within 120 days after the end of our fiscal year ended June 30, 2026.
The reference on the cover page of the Original Report to such incorporation by reference has been deleted and the number of shares of Common Stock outstanding has been updated. This Form 10-K/A amends and restates in their entirety Items 10 through 14 of Part III of the Original Report. Capitalized terms not otherwise defined in Part III of this Form 10-K/A shall have the same meanings assigned to those terms in Parts I and II of the Original Report.
In addition, in connection with the filing of this Form 10-K/A and pursuant to the rules of the SEC, we are including in this Form 10-K/A new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed as Exhibits 31.3 and 31.4 to this Form 10-K/A. Item 15 of Part IV of the Original Report is amended solely to add these certifications to the exhibit index, and the exhibit index and the exhibits filed with the Original Report are not otherwise amended or restated. Because no financial statements are included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Because no financial statements are contained in this Form 10-K/A, we are not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Except as described above, this Form 10-K/A does not modify or update the disclosures in, or any exhibits to, the Original Report. Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect any events which occurred subsequent to the filing of the Original Report. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the Original Report was filed.
Unless otherwise specified or indicated by the context, “Bio-Techne,” the “Company,” “we,” “us” and “our” refer to Bio-Techne, its divisions and subsidiaries.
TABLE OF CONTENTS
Showing the first 8K of 157K characters. Open the full section
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS
EQUITY COMPENSATION PLAN INFORMATION
We currently award stock-based compensation, including stock options and restricted stock units, under the 2020 Equity Incentive Plan. The following table presents information about common stock authorized for issuance under that plan as of June 30, 2026:
| Plan Category | Number of Securities to be Issued Upon Exercise of Outstanding Options (# in 000’s) | Weighted Avg. Exercise Price of Outstanding Options ($) | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (A)) (# in 000’s) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) | (B) | (C) | |||||||||||
| Equity compensation plans approved by shareholders | 6,991 | $ | 73.47 | 5,876 | |||||||||
| Equity compensation plans not approved by shareholders | - | N/A | - | ||||||||||
| Total | 6,991 | 73.47 | 5,876 |
As of October 9, 2026, there were 5,242,909 shares available for future grants under the 2020 Equity Incentive Plan, and the closing price per share of our common stock was $72.46 as reported on The Nasdaq Global Select Market.
Principal Shareholders
The following table provides information concerning the only persons known to the Company to be the beneficial owners of more than 5% of the Company’s outstanding common stock as of October 9, 2026.
| Name and Address of Beneficial Owner | Amount and Nature of Shares Beneficially Owned | Percent of Class | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Vanguard Capital Management | ||||||||||
| 11,559,571 | (1) | 7.4 | % | |||||||
| BlackRock, Inc. | ||||||||||
| 11,011,556 | (2) | 7.0 | % | |||||||
| FMR LLC | ||||||||||
| 12,754,784 | (3) | 8.1 | % |
| (1) | Based solely on information contained in a Schedule 13G, filed with the SEC on April 29, 2026, by Vanguard Capital Management (“VCM”), in which VCM reported that, as of March 31, 2026, it had sole voting power as to 1,379,862 shares of Bio-Techne Common Stock and sole dispositive power as to 11,559,571 shares of Bio-Techne Common Stock. The address of VCM is 100 Vanguard Boulevard, Malvern, Pennsylvania 19355. |
|---|
| (2) | Based solely on information contained in a Schedule 13G/A, filed with the SEC on July 16, 2025, by BlackRock, Inc. (“BlackRock”), in which BlackRock reported that, as of June 30, 2025, it had sole voting power as to 10,333,812 shares of Bio-Techne Common Stock and sole dispositive power as to 11,011,556 shares of Bio-Techne Common Stock. The address of BlackRock is 50 Hudson Yards, New York, New York 10001. |
|---|
| (3) | Based solely on information contained in a Schedule 13G/A, filed with the SEC on August 6, 2026, by FMR LLC (“FMR”), in which FMR reported that, as of June 30, 2026, it had sole voting power as to 12,715,889.05 shares of Bio-Techne Common Stock and sole dispositive power as to 12,754,783.64 shares of Bio-Techne Common Stock. The address of FMR is 245 Summer Street, Boston, Massachusetts 02210. |
|---|
Management Shareholdings
The following table sets forth the number of shares of the Company’s common stock beneficially owned as of October 9, 2026, by each named executive officer, by each director, and by all directors and current executive officers as a group. Each individually beneficially owns less than one percent of total shares outstanding, which includes shares subject to options such individual may exercise. As a group, executive officers and directors beneficially own 1.3% of total shares outstanding.
| Name of Director or Executive Officer | Number of Shares Beneficially Owned(1) | % Owned | |||
|---|---|---|---|---|---|
| Robert V. Baumgartner | 108,265 | (2) | * | * | |
| Joseph Keegan, Ph.D. | 66,792 | (3) | * | * | |
| John L. Higgins | 128,635 | (4) | * | * | |
| Alpna Seth, Ph.D. | 46,700 | (5) | * | * | |
| Dr. Rupert Vessey, MA, BM BCh, FRCP, DPhil | 44,628 | (6) | * | * | |
| Julie L. Bushman | 33,464 | (7) | * | * | |
| Dr. Judith Klimovsky | 12,680 | (8) | * | * | |
| Dr. Amy Herr | 20,417 | (9) | * | * | |
| Kim Kelderman | 390,300 | (10) | * | * | |
| James Hippel | 497,202 | (11) | * | * | |
| William Geist | 111,317 | (12) | * | * | |
| Shane Bohnen | 53,470 | (13) | * | * | |
| Steven Crouse | 85,550 | (14) | * | * | |
| Matthew McManus | 7,691 | (15) | * | * | |
| Officers and directors as a group (13 persons) | 1,999,708 | (16) | 1.3 | % |
| * | Indicates less than 1.0% ownership of the Company’s shares. |
|---|
| (1) | Unless otherwise indicated, the person listed as the beneficial owner has sole voting and sole investment power over outstanding shares. Shares beneficially owned includes shares underlying restricted share awards that are currently outstanding, shares underlying restricted stock units that are currently outstanding and vested or will vest within 60 days of October 9, 2026, shares underlying options that are currently outstanding and exercisable and options that are currently outstanding and will become exercisable within 60 days of October 9, 2026. Percentage ownership calculations are based on 157,055,564 shares issued and outstanding on October 9, 2026. |
|---|
| (2) | Includes 56,884 shares held directly and 51,381 shares subject to vested but unexercised share options. |
|---|
| (3) | Includes 15,411 shares held directly and 51,381 shares subject to vested but unexercised share options. |
|---|
| (4) | Includes 77,254 shares held directly and 51,381 shares subject to vested but unexercised share options. |
|---|
| (5) | Includes 15,411 shares held directly and 31,289 shares subject to vested but unexercised share options. |
|---|
| (6) | Includes 10,987 shares held directly and 33,641 shares subject to vested but unexercised share options. |
|---|
| (7) | Includes 8,775 shares held directly and 24,689 shares subject to vested but unexercised share options. |
|---|
| (8) | Includes 3,782 shares held directly and 8,898 shares subject to vested but unexercised share options. |
|---|
| (9) | Includes 2,680 shares held directly and 6,192 shares subject to vested but unexercised share options. Additionally, includes 576 shares held by Dr. Herr’s partner and 10,969 shares subject to vested but unexercised share options. |
|---|
| (10) | Includes 82,762 shares held directly and 307,538 shares subject to vested but unexercised share options. |
|---|
| (11) | Includes 170,183 shares held directly, 315,474 shares subject to vested but unexercised share options and 11,545 restricted stock units that vest within 60 days of October 9, 2026. |
|---|
| (12) | Includes 24,943 shares held directly and 86,374 shares subject to vested but unexercised share options. |
|---|
| (13) | Includes 10,360 shares held directly and 43,110 shares subject to vested but unexercised share options. |
|---|
| (14) | Includes 10,237 shares held directly and 75,313 shares subject to vested but unexercised share options. |
|---|
| (15) | Dr. McManus’ employment with the Company terminated effective April 1, 2026. The amount shown is based on his most recent Form 4, filed with the SEC on February 3, 2026. |
|---|
| (16) | Includes 400,288 shares of Bio-Techne Common Stock held by Bio-Techne’s Stock Bonus Plan, as to which the Board directs the voting, 489,669 shares held directly, 576 shares held by Dr. Herr’s partner, 1,097,630 shares subject to options that are currently exercisable or will become exercisable within 60 days of October 9, 2026, and 11,545 restricted stock units that vest within 60 days of October 9, 2026. |
|---|
Changes in Control
As described above, on June 25, 2026, the Company entered into the Merger Agreement with Parent and Merger Sub, pursuant to which, on the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent. Completion of the Merger will result in a change in control of the Company.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Related Party Transactions
As provided in its charter, the Nominations and Governance Committee reviews and approves all related party transactions involving the Company’s directors and executive officers or their immediate family members to determine whether such transactions meet applicable legal requirements and are appropriately disclosed. The Company has adopted a written policy concerning the review of related party transactions, which provides that, in determining whether to approve or ratify a related party transaction, the Nominations and Governance Committee will take into account, among other factors it deems appropriate, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction. In addition, the Company’s Code of Ethics and Business Conduct requires all directors and executive officers to inform the Company’s legal counsel of any existing or proposed relationship or business transaction that could be, or might appear to be, a conflict of interest. Any reported transactions would be brought to the attention of the Nominations and Governance Committee for review and disposition. Since the beginning of the last fiscal year, there have been no related party transactions requiring disclosure under applicable rules and regulations.
Board Independence
Bio-Techne’s Principles of Corporate Governance provide that a majority of the Board must be independent directors under criteria established by the Board in conformity with the listing rules of the Nasdaq Stock Market. The Nominations and Governance Committee annually reviews the independence of each director, including whether there are any related party transactions. In making its most recent independence determinations, the Nominations and Governance Committee reviewed transactions and relationships between each director or any member of a director’s immediate family on one side, and the Company or any of its subsidiaries on the other side, based on information provided by the directors and from Company records and publicly available information. The Committee determined and the Board confirmed that all of the Company’s non-employee directors are independent. When Dr. Herr was appointed to the Board in fiscal year 2025, the Company noted that her partner was an employee (a non-executive officer) of a Bio-Techne subsidiary whose compensation from the Company was strictly in connection with his employment. In conjunction with Dr. Herr’s selection and formal appointment, the Board determined that this relationship, including her partner’s level and role within the Company’s subsidiary, would not undermine her ability to make decisions as a director. Accordingly, the Board determined Dr. Herr to be an independent director, and implemented additional compliance safeguards to assist Dr. Herr and her partner in maintaining her independent status.
| ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES |
|---|
Audit Fees
The following fees were paid or payable to KPMG LLP for the fiscal years ended June 30, 2026 and 2025 (in thousands):
| 2025 ($) | 2026 ($) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Audit Fees | $ | 2,377 | $ | 2,447 | |||||
| Audit-Related Fees | 110 | 110 | |||||||
| Tax Fees | 254 | 123 | |||||||
| All Other Fees | - | - |
“Audit Fees” are for professional services rendered and expenses incurred for the audit of the Company’s annual financial statements and review of financial statements included in our Forms 10-K and 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements. Audit Fees also included fees incurred for the audit of the effectiveness of our internal controls over financial reporting.
“Audit-Related Fees” are mainly for agreed-upon procedures (agreed-upon or expanded audit procedures related to accounting records required to respond to or comply with financial, accounting, or regulatory matters). Audit-Related Fees for fiscal year 2025 included $100,000 for ESG reporting readiness services relating to fiscal years 2024 and 2025.
“Tax Fees” for fiscal year 2026 included $123,000 for domestic and international tax return preparation services and tax compliance and consulting services.
“Tax Fees” for fiscal year 2025 included fees for services provided and expenses incurred in connection with (i) preparation of the Company’s tax returns in the United States, Germany, and the United Kingdom and inquiries and audits related to such returns, $118,000; and (ii) tax consulting, $136,000.
Pre-Approval Policies and Procedures
Pursuant to its written charter, the Audit Committee is required to pre-approve the audit and non-audit services performed by the Company’s independent registered public accounting firm. The Audit Committee may delegate to one or more of its members the authority to grant pre-approvals so long as such pre-approvals are reported to and reviewed by the full Committee at its next meeting. Annual tax services are reviewed and approved by the Audit Committee prior to the commencement of such services. All of the services rendered by KPMG LLP in fiscal years 2026 and 2025 were pre-approved by the Audit Committee.
PART IV
| ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
|---|
Item 15 of Part IV of the Original Report is hereby amended solely to add the exhibits listed below. No financial statements or financial statement schedules are filed with this Form 10-K/A, and the exhibit index included in the Original Report is not otherwise amended or restated.
Exhibit Index
| Exhibit Number | Description | |
|---|---|---|
| 31.3 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.4 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment No. 1 on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIO-TECHNE CORPORATION | |||
|---|---|---|---|
| Date: October 28, 2026 | /s/ James Hippel | ||
| By: | James Hippel | ||
| Its: | Executive Vice President, Chief Financial Officer |